ArticleScientific reports2025
In vitro evaluation and phytochemical analysis of Curcuma aeruginosa Roxb. against human coronavirus OC43.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curcuma aeruginosa Roxb. is traditionally used across Southeast Asia in various cultural and medicinal practices. Its rhizome contains terpenes and has historically been employed to treat fever and gastrointestinal disorders-symptoms often associated with coronavirus infections. Large intestinal epithelial cells serve as potentially significant sites for viral replication, with pronounced susceptibility to human coronaviruses, and present promising targets for antiviral therapeutic interventions. This study investigated the phytochemicals in C. aeruginosa rhizome extracts using different extraction solvents and measured their inhibition against human coronavirus OC43 (HCoV-OC43) replication activities in the large intestine adenocarcinoma cell line (HCT-8). Extracts using hexane, ethyl acetate, ethanol, or methanol were quantified for curcumenol and furanodienone using HPLC, with GC-MS/MS utilized for phytochemical analysis. The inhibition of HCoV-OC43 replication was evaluated using in-cell ELISA. The crude hexane extract of C. aeruginosa rhizome demonstrated the highest inhibitory activity, with the greatest amounts of curcumenol and furanodienone (59.56 ± 1.56 and 5.70 ± 0.26 mg/g, respectively) compared to the other crude extracts from different solvents. In GC-MS/MS analysis, curcumenol was identified as the major component in C. aeruginosa rhizome crude extracts, serving as a potential active marker for this plant. The findings indicated that C. aeruginosa hexane extract showed significant therapeutic potential for future antiviral applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.